Clinical trials targeting tau should be halted.

Experimental drugs lowering brain tau are heralded as improvements in the treatment of Alzheimer's disease. However, the outcomes in clinical trials testing these agents have consistently failed to improve patient outcomes, i.e. slow down disease or improving cognition. Furthermore, the scientific rationale behind such drugs is rather poor in the first place and has been questioned. Therefore, I argue that trials of anti-tau drugs should be halted.